Culture Collections

Cell Lines Coming Soon to ECACC

All cell lines that feature in this coming soon section have not currently gone through the banking process and therefore have not passed any Quality Control testing. Availability of these lines will only be possible once they have been processed through our Banking Procedures and have completed all Quality Control testing.

To register that you are interested in any of the below cell lines please submit a technical enquiry stating which cell lines you are interested in.

 

Mouse Fibrosarcoma Cell Line Collection

A collection of 8 Mouse fibrosarcoma cell lines, deposited by Ximbio, which are capable of expressing all vascular endothelial growth factor (VEGF) isoforms (known as the Control cell lines) or only single isoforms of VEGF (VEGF120, VEG164, or VEG188). These were developed under endogenous VEGF promotor control.

Vascular endothelial growth factor-A (VEGF) is producted in multiple isoforms by most cancer cells, which display distinct biological activities. VEGF plays an undisputed role in tumour growth, vascularisation and metastasis. The detailed functions of individual isoforms in these processes remain poorly understood. The research group led by Gillian Tozer at the Tumour Microcirculation Group, Department of Oncology and Metabolism, University of Sheffield Schoolm United Kingdom, have investigated the effects of three main murine isoforms (VEGF120, 164 and 188) on tumour cell behaviour, using a panel of fibrosarcoma cells they developed that express each isoform individually under the control of their endogenous promotor control. These cell lines are deposited within the ECACC General Collection by Ximbio.

Cells are available in a non-fluroscent and fluorescent form, with the latter expressing Luciferase2 and mStrawberry to allow optical imaging of tumour deposits.

Catalogue Number  Cell Line Name
 17100507  Mouse fibrosarcoma VEGFWT (Control)
 17100508  Mouse fibrosarcoma VEGF188
 17100509  Mouse fibrosarcoma VEGF120
 17100510  Mouse fibrosarcoma VEGF164
 17100518  Mouse fibrosarcoma Luciferase2 mStrawberry VEGFWT (Control)
 17100526  Mouse fibrosarcoma Luciferase2 mStrawberry VEGF120
 17100527  Mouse fibrosarcoma Luciferase2 mStrawberry VEGF164
 17100528  Mouse fibrosarcoma Luciferase2 mStrawberry VEGF188

 

HCT 116 Derivatives 

Recent studies by the Drug Resistance Group, Queen's University Belfast, has shown that anticancer drugscan trigger the activation of human epidermal receptor (HER) survival pathways in colorectal cancer (CRC). Chemotherapy (5-fluorouracil) treatment has been shown to result in acute increase in transforming growth factor-α, amphiregulin, and heregulin ligand shedding in vitro and in vivo correlating with significantly increased ADAM-17 activity. ADAMs (a desintergrin and metalloproteases family), specifically ADAM-17 is involved in regulating HER1 activation.

The cell line HTC 116 ADAM17, deposited by Ximbio, was developed to stably overexpress HA-tagged ADAM-17. Western blot analysis identified TGF-α, AREG and heregulin shredding and an increase in EGFR and HER3 activation compared to the empty vector control line.

Catalogue Number Cell Line Name
 17031402 HCT 166  ADAM17                                                              

 

ALX is a member of the TAM (Tyro3, AXL and MER) receptor tyrosine kinase family. It is ubiquitously expressed and detected in a wide variety of cells and has been reported in a wide variety of cancers. Receptor tyrosine kinase (RTK) screens identified AXL as a protein which underpins the migratory/invasive phenotype in colorectal cancer (CRC). AXL was shown to be a poor prognostic marker and an important mediator of cell migration/invasiveness. HCT 116 AXL KO Tet-inducible cell line, deposited by Ximbio, enables further investigation into the target as a prognostic biomarker and therapeutic target.

Catalogue Number Cell Line Name
 17031404 HCT 116 AXL Tet-inducible                                                   

 

EphA2 (Eph receptor tyrosine kinase family) is an important regulator of tumour initation, neo-vascularisation and metastasis in a range of epithelial and mesenchymal cancers. It has structural homology and affinity for binding the GPI-anchored Ephrin-A.

The HCT 116 EphA2 KO Tet-inducible cell line, deposited by Ximbio, was developed to address the involvement of EphA2 where it was shown that silencing of the protein suppressed migration and invasion. EphA2 is overexpressed in invasive colorectal cancer and correlates with increased expression of stem cell marker CD44. Expression levels are regulated by KRAS through the MAPK and RalGDS-RalA pathways.

Catalogue Number Cell Line Name
 17031406 HCT 116 EphA2 KO Tet-inducible                                          

 

The Epithelial-Mesenchymal transition (EMT) has been suggested to play a role in the initial invasion step during cancer metastasis.

The HCT 116-I6 Invasive cell line, deposited by Ximbio, is a sub-line of HCT 116 that demonstrates a 4- and 20-fold increase in migration and invasion rate respectively, compared to the parental HCT 116 cell line. The increased migratory/invasion capacity seen in HCT 116-I6 cells is a stable event and not due to increased proliferation rates. In contrast to the parental line, the HCT 116-I6 Invasive cell line has transitioned to a spindle-shaped mesenchymal-like morphology. In keeping with the changes observed in EMT, a loss of E-cadherin (a well-known epithelial marker) and a gain of mesenchymal marker SNAIL was observed. CD44 expression was found to be 4-fold higher. There was a decreased level of TGF-α and amphiregulin with a decreased basal activity of EGFR, HER2 and IGF-IR.

Catalogue Number Cell Line Name
 17031408 HCT 116-I6 Invasive                                                          

 

Babraham Institute Cell Lines

HM3 cells are HEK 293 cells stably expressing conditional kinase ΔMEKK3:ER* from the pBabePuro plasmid. ΔMEKK3:ER* consists of the isolated kinase domain of MEKK3 fused in-frame to a modified form of the hormone binding domain of the oestrogen receptor (hbER*) that can be de-repressed by 4-hydroxytamoxifen (4-HT) but not β-estradiol. In this case, the * refers to a point mutation that ablates estradiol binding but allows 4-HT binding.

Activation of the ΔMEKK3:ER* leads to the strong activation of the JNK and p38 pathways and a weaker activation of ERK1/2. This cell line, deposited by Ximbio, can be used to study the role and factors impacting on the JNK, p38 and ERK1/2 signalling pathways such as gene expression, cell proliferation, cell cycle arrest and cell death. The cells are puromycin resistant. Conditional kinase activation of ΔMEKK3:ER* can be induced with 100nM 4-HT.

Catalogue Number Cell Line Name
 17031410 HM3                                                                                   

 

HR1 cells are HEK 293 cells stably expressing conditional kinase ΔRaf-1:ER* from the pCMV Neo Myc plasmid. ΔRaf-1:ER* (also known as ΔCRAF:ER*) consists of the isolated kinase domain of c-Raf1 fused in-frame to a modified form of the hormone binding domain of the oestrogen receptor (hbER*) that can be de-repressed by 4-hydroxytamoxifen (4-HT) but not β-estradiol. In this case the * refers to a point mutation that ablates estradiol binding but allows 4-HT binding.

Activation of ΔRaf-1:ER* leads to the selective activation of the ERK1/2 pathway. This cell line, deposited by Ximbio, can be used to study the cellular role and factors impacting on the ERK1/2 signalling pathway such as gene expression, cell proliferation, cell cycle arrest and cell death. The cells are G418 resistant. Conditional kinase activation of ΔRaf-1:ER* can be induced with 100nM of 4-HT.

Catalogue Number Cell Line Name
 17031412 HR1                                                                                   

 

Cancer Research UK Glasgow – The Beatson Institute

Fumarate hydratase - which can be found in either a mitochondrial or cytosolic form - is an enzyme that catalyses the reversible hydration and dehydration of fumarate to malate. Signal sequences located in the protein dictate the subcellular location of each FH isoenzyme. The cytosolic form is involved in the metabolism of amino acids and fumarate and the mitochondrial form is involved in the Krebs Cycle (tricarboxylic acid cycle or the citric acid cycle). Germline mutations of FH are responsible for hereditary leiomyomatosis and renal-cell cancer (HLRCC)1.

FH fl/fl is a conditional knock-out model in which the deletion of fumarate hydratase can be achieved by intracellular expression of Cre recombinase. FH -/- CL1 and FH -/- CL19 cell lines are Knock-out models. All three lines were developed from Mouse kidney tissue and deposited into the collection by Ximbio.

Catalogue Number Cell Line Name
 17100519 FH fl/fl 
 17100520 FH -/- CL1 
 17100521 FH -/- CL19                                                                         

 

Succinate dehydrogenase (SDH) is a enzyme complex found in the inner mitrochondrial membrane of mammalian mitochondria and many bacterial cells. SDH is the only enzyme that participates in both the electron transport chain and citric acid cycle. The enzymatic function of SDH oxidises succinate to fumarate in the tricarboxylic acid cycle and losing this function is associated with cancer formation.

SDH fl/fl is a conditional knock-out model in which the deletion of succinate dehydrogenase can be achieved by intracellular expression of Cre recombinase. SDH -/- CL5 and SDH -/- CL7 cell lines are Knock-out models. All three lines were developed from Mouse kidney tissue and deposited into the collection by Ximbio.

Catalogue Number Cell Line Name
 17100522 SDH fl/fl
 17100523 SDH -/- CL5
 17100524 SDH -/- CL7                                                                        

 

Cancer Research UK London Research Institute: Lincoln's Inn Fields

 The Gamma2A Jak2 cell line, deposited by Ximbio, has been developed by expressing protein tyrosine kinase JAK2 in a mutant cell line defective in the interferon-gamma signal transduction pathway. By using this cell line, the structural and functional analysis of JAK2 in IFN-gamma signalling has been examined. The cell line revealed that the specificity of JAK may lie mainly in their structural ineraction with different receptors and signalling proteins rather than in the substrate specificity of their kinase domains.

Catalogue Number Cell Line Name
 17011203 Gamma2A Jak2 Cell Line                                                      

 

The E3 cell line, deposited by Ximbio, is an immortalised Mouse mammary cell line which was developed to examine the possibility of using the MUC1 gene and its products in active immunisation against breast and other carcinomas. The human MUC1 gene codes for a type I membrane glycoprotein that is normally expressed on the apical surface of most glandular epithelial cell, but which is upregulated and under- or differently glycosylated in carcinomas; these differences in glycosylation lead to the exposure of novel epitopes which are not found on the normally processed mucin and can therefore be used as targets.

In addition to this a further cell line was developed; E2 STn, a mouse mammary carcinoma cell line E3 which expresses human MUC1 and Sialyl-Tn. Changes in the composition of glycans added to glycoproteins and glycolipids are characteristic of the change to malignancy. Sialyn-Tn (STn) is expressed by 25-20% of breast carcinomas but its expression on normal tissue is highly restricted. Sialyl-Tn is an O-linked disaccharide that can be carried on various glycoproteins. One such glycoprotein MUC1 is expressed by the vast majority of breast carcinomas. Both STn and MUC1 have been considered targets for immunotherapy of breast cancer patients.

Catalogue Number Cell Line Name
 17011204 E3 Cell Line
 17011205 E3 STn Cell Line                                                                 

 

The CHO ICAM-1Fc cell line, deposited by Ximbio, was developed from the parental Chinese Hamster Ovary (CHO) and is a transgenic model. CHO ICAM-1Fc cells secrete a dimeric human ICAM-1Fc protein. ICAM-1 (CD54) is a major ligand for leukocyte CD11/CD18 integrins and used in adhesion assays to evaluate integrin activity.

Human ICAM-1Fc chimeric protein (five extracellular domains of ICAM-1 plus hinge, CH2 and CH3 domains of IgG1) is the protein target related to this cell line.

Catalogue Number

Cell Line Name
 17011208 CHO ICAM-1Fc Cell Line                                                       

 

King's College London

The parental T47D cell line, deposited by Ximbio, was estabilished from the pleural effusion of a ductal carcinoma of the breast. The tumour cell line, T47D-E2J, was created as a breast cancer model with an O-linked glycosylation profile similar to normal mammary epithelial cells. T47D-E2J cells overexpress the enzyme C2GnT1, a beta-1,3-galactosyl-O-glycosyl-glycoprotein.

C2GnT1 is the dominant enzyme expressed in normal breast tissue known to convert core 1 glycoproteins to core 2 glycoproteins, by the addition of N-acetylglucosamine to N-acetylgalactosamine. Expression of the C2GnT1 enzyme has been found to be decreased or absent in most breast cancer cell lines despite still expressing mRNAs coding for this enzyme.

The tumour cell line, T47D-STn, was created as a breast cancer model which expresses the Sialyl-Tn, STn, antigen. These cells overexpress the enzymes C2GnT1,  a beta-1,3-galactosyl-O-glycosyl-glycoprotein and glycosyltransferase, ST6GalNAc-I. ST6GalNAc-I which is found throughout the Golgi, can catalyse the transfer of sialic acid to N-acetylgalactosamine and is predominately limited to the gastrointestinal tract in normal adult tissues. Expression of ST6GalNAc-I in human cells promotes formation of the STn antigen which is a saccharide structure (N-acetylgalactosamine) lines to serine or threonine by a glycosidic bond. STn antigens are not usually found on health cell surfaces but often on human breast cancer cells. 

Catalogue Number Cell Line Name
 17011207 T47D-E2J Cell Line 
 17011206 T47D-E2J Cell Line                                                              

 

University of Dundee

The U-2 OS Gal4-p300 cell line, deposited by Ximbio, is a human Osteosarcoma cell line developed by the University of Dundee. U2-OS cells expressing Gal4-p300, a transcriptional coactivator that functions as an integrator of numerous signalling pathways is utilised by many DNA binding proteins to facilitate transcriptional activation. p300 shares numerous conserved domains with CREB binding protein (CBP), which is also a transcriptional coactivator. These shared domains include a histone acetyl transferase (HAT) domain, a bromo domain, and three cysteine- and histidine-rich domains. CBP also interacts with the RNA polymerase II holoenzyme and p300/CBP both contain transcriptional activation domains that function independently of HAT activity.

Catalogue Number Cell Line Name
 17011202 U-2 OS Gal4-p300                                                               

 

Miami Cell Lines

Human Ovarian Cancer Cell Line Collection

The U-2 OS Gal4-p300 cell A new set of 15 ovarian cancer cell lines are being accessioned into the ECACC General Cell Collection. These new lines have been characterised to ensure the genomic landscape, histopathology and molecular features of the original tumours is maintained. The new collection is a valuable resource for the study of ovarian cancers and therapeutic development for their treatment, providing a greatly improved platform for in vitro and xenograft based investigations into high-grade, poorly differentiated ovarian cancers. Clear cell, Serous, Mullerian, Endometrioid, Carcinosarcoma and Mucinous tumour histologies are represented along with p53, PI3K and BRCA2 mutants identified.

Catalogue Number Cell Line Name
 20012001 OCI-C1p                                                                             
 20012002 OCI-C4p
 20012003 OCI-C5x
 20012004 OCI-P2a
 20012005 OCI-P5x
 20012006 OCI-P7a
 20012007 OCI-P8p
 20012008 OCI-P9a1
 20012009 FCI-P2p
 20012010 OCI-CSp
 20012011 OCI-U1a
 20012012 OCI-E1p
 20012013 OCI-EP1p
 20012014 OCI-M1p
 20012015 OCI-P9a2

 

Ovarian and Fallopian Tube Cell Line Collection

Cells from the ovarian and fallopian tube cell lines were harvested from two post-menopausal female doctors aged 56 and 65, respectively, during surgical treatment for benign gynaecological conditions. These cell lines display evidence of increased resistance to Cisplatin and Taxol when compared to standard ovarian cancer lines, which suggests that in vitro drug responses of these lines correlate closely with in vivo patient responses. These cell lines are offered as an immortalised 'normal' line (OCE1, OCE2, FNE1, FNE2), a transformed line (OCLE1, OCLE2, FNLE1, FNLE2), and a tumourigenic line (OCLER1, OCLER2, FNLER1, FNLER2). The OCE cell line is consistent with ovarian surface/inclusion cyst epithelium while FNE cells are similar to those of non-cilliated epithelium found in the fallopian tube in mouse xenograft models when compared to normal human ovaries and fallopian tubes.

Catalogue Number Cell Line Name                                                                      
 20012016 OCE1
 20012017 OCLE1
 20012018 OCLER1
 20012019 OCE2
 20012020 OCLE2
 20012021 FNLER2
 20012022 FNE1
 20012023 FNLE1
 20012024 FNLER1
 20012025 FNE2
 20012026 FNLE2

 

Breast Epithelial Cell Line Collection

Breast Epithelial cell lines were established from patients who underwent disease free reduction mammoplasties and were aged between 26 and 48 years old. These cell lines were derived from the same originating patients and are offered as immortalised 'normal' line (BPE1, BPE2, BPE3, BPE4 and HME2, HME3, HME4), a transformed line (BPLE1, BPLE2, BPLE3, BPLE4 and HMLE2, HMLE3, HMLE4), and a tumourigenic line (BPLER1, BPLER2, BPLER3, BPLER4 and HMLER2, HMLER3, HMLER4). The gene expression vectors were sequentially introduced to recipient cells in individual steps in the following order: pmig-GFP-hTERT expressing cells relative to their corresponding normal cell type.

Catalogue Number Cell Line Name                                                                
 20012027 BPE1
 20012028 BPLE1
 20012029 BPLER1
 20012030 BPE2
 20012031 BPLE2
 20012032 BPLER2
 20012033 BPE3
 20012034 BPLE3
 20012035 BPLER3
 20012038 BPLER4
 20012039 HME2
 20012040 HMLE2
 20012041 HMLER2
 20012042 HME3
 20012043 HMLE3
 20012044 HMLER3
 20012045 HME4
 20012046 HMLE4
 20091601 HMLER4

 

Dublin City University Collection

A number of cancerous, drug resistant cell lines have been deposited by Dublin City University.

The DLKP family of cells are taken from a poorly differentiated lung squamous cell carcinoma, established from a lymph node biopsy of a 52-year-old male. Several sub-populations of this cell line will be available in our General Cell Collection (Acc Nos. 20082601-20082604), with various lines showing tumourigenicity in SCID-Mice strain CB17/Icr-Prkdcscid. A number of these lines are Adriamycin-resistant (Acc Nos. 20082607-20082609 and 20091601) and Mitoxantrone-resistant (Acc Nos. 20082605-20082606).

They have also deposited some drug resistant variants of the SK MES 1 cell line, a Human Caucasian lung squamous carcinoma, with us. These lines show resistance to Taxotere and Adriamycin. The final cell line is an Adriamycin-resistant variant of OAW42, a human ovarian tumour derived from an ascites of a patient with ovarian cystadenocarcinoma (Acc No. 20082613).

Catalogue Number Cell Line Name                                                                
 20082601 DLKP
 20082602 DLKP-I
 20082603 DLKP-M
 20082604 DLKP-SQ
 20082605 DLKP-SQ-Mitotox-BCRP
 20082606 DLKP-SQ-Mitotox-MDR
 20082607 DLKP-A
 20082608 DLKP-A5F
 20082609 DLKP-A10F
 20082610 DLRP
 20082611 SKMES-1-A
 20082612 SKMES-1-Txt
 20082613 OAW42-A
 20091601 DLKP pHaMDR/A

 

Unite du Virologie et Immunologie Moléculaires, Institut National de la Recherche Agronomique (INRAE), France

The Molecular Virology and Immunology Unit, National Institute of Agronomic Research in France, alongside the Aquatic and Fish Health, Marine Scotland, Aberdeen, Scotland, UK have deposited a Chinook Salmon (Oncorhynchus tshawytscha) cell line into our General Cell Collection. This genetically modified cell line is derived from CHSE-214 (Acc No. 91041114); and permanently expresses a monomeric form of the Enhanced Green Fluorescent Protein (mEGFP) and is resistant to G418. It is susceptible to a wide range of fish viruses and in many instances, replicates high titres.

Catalogue Number Cell Line Name
 20090901 CHSE-E                                                                             

 

Translational and Clinical Research Institute, Newcastle University, UK

The AR42J-B13 cell is a readily expandable rat pancreatic acinar-like cell that differentiates on simple plastic culture substrata into replicatively-senescent hepatocyte-like (B-13/H) cells in response to glucocorticoid exposure. B-13/H cells express a variety of liver-enriched and liver-specific genes, main at levels similar to hepatocytes in vivo. Furthermore, the B-13/H phenotype is maintained for at least several weeks in vitro, in contrast to normal hepatocytes which rapidly de-differentiate under the same simple- or even more complex- culture conditions. These cells will provide an unlimited supply of hepatocyte-like cells for liver and toxicology studies.

Catalogue Number Cell Line Name
 20100101 AR42J-B13                                                                         

 

 

 

 

Back to top
Copyright © Public Health England.

Please confirm your country of origin from the list below.